LifeStance Health Group (NASDAQ:LFST) Price Target Raised to $15.00

LifeStance Health Group (NASDAQ:LFST) had its price objective raised by KeyCorp from $13.00 to $15.00 in a research report report published on Monday morning,Benzinga reports. The brokerage currently has an overweight rating on the stock.

LFST has been the topic of a number of other research reports. JPMorgan Chase & Co. lifted their price target on shares of LifeStance Health Group from $9.00 to $13.00 and gave the stock a “neutral” rating in a report on Friday, August 14th. Barclays increased their price objective on LifeStance Health Group from $13.00 to $15.00 and gave the company an “overweight” rating in a report on Thursday, September 10th. BTIG Research raised their target price on LifeStance Health Group from $16.00 to $18.00 and gave the stock a “buy” rating in a research report on Wednesday, August 19th. Wall Street Zen downgraded LifeStance Health Group from a “strong-buy” rating to a “buy” rating in a report on Saturday, September 5th. Finally, Canaccord Genuity Group lifted their target price on LifeStance Health Group from $13.00 to $15.00 and gave the stock a “buy” rating in a report on Wednesday, September 9th. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and four have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $13.12.

LifeStance Health Group Stock Performance

Shares of LFST stock opened at $12.11 on Monday. The firm has a market capitalization of $4.63 billion, a price-to-earnings ratio of 93.16 and a beta of 1.24. The company has a current ratio of 1.38, a quick ratio of 1.38 and a debt-to-equity ratio of 0.18. The business’s 50-day moving average price is $12.14 and its 200-day moving average price is $9.70. LifeStance Health Group has a 12 month low of $4.77 and a 12 month high of $13.56.

LifeStance Health Group (NASDAQ:LFST) last released its quarterly earnings data on Thursday, August 6th. The company reported $0.06 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.03 by $0.03. LifeStance Health Group had a return on equity of 3.39% and a net margin of 3.19%.The company had revenue of $435.35 million during the quarter, compared to the consensus estimate of $414.58 million. During the same quarter in the prior year, the firm posted ($0.01) earnings per share. The firm’s revenue was up 26.1% compared to the same quarter last year. Equities research analysts forecast that LifeStance Health Group will post 0.16 EPS for the current year.

Insider Buying and Selling at LifeStance Health Group

In other news, COO Lisa K. Miller sold 47,912 shares of LifeStance Health Group stock in a transaction on Monday, August 10th. The shares were sold at an average price of $10.85, for a total value of $519,845.20. Following the completion of the sale, the chief operating officer owned 281,289 shares in the company, valued at $3,051,985.65. The trade was a 14.55% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, major shareholder Tpg Gp A, Llc sold 13,643,207 shares of LifeStance Health Group stock in a transaction on Monday, August 10th. The shares were sold at an average price of $10.62, for a total transaction of $144,890,858.34. Following the completion of the sale, the insider owned 98,101,407 shares of the company’s stock, valued at $1,041,836,942.34. This represents a 12.21% decrease in their position. The SEC filing for this sale provides additional information. Over the last three months, insiders have sold 13,777,580 shares of company stock valued at $146,433,781. 3.50% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Silversmith Partners I GP LLC bought a new stake in LifeStance Health Group in the fourth quarter valued at $100,842,000. Bank of America Corp DE bought a new position in shares of LifeStance Health Group during the 2nd quarter worth about $14,987,000. Moran Wealth Management LLC bought a new position in shares of LifeStance Health Group during the 1st quarter worth about $953,000. Orbimed Advisors LLC acquired a new stake in shares of LifeStance Health Group in the 1st quarter valued at about $3,185,000. Finally, The Manufacturers Life Insurance Company bought a new stake in LifeStance Health Group in the 2nd quarter valued at about $966,000. 85.50% of the stock is owned by institutional investors.

LifeStance Health Group Company Profile

LifeStance Health Group, Inc is a U.S.-based healthcare company that provides outpatient mental health services through a network of clinicians. Its services are delivered through both in-person appointments and a virtual care platform, allowing patients to access care in a range of settings.

The company offers psychiatric evaluation and treatment, psychotherapy, medication management, psychological and neuropsychological testing, and related behavioral health services. LifeStance serves children, adolescents, and adults, addressing conditions such as anxiety, depression, attention-deficit/hyperactivity disorder, and other mental health and behavioral concerns.

LifeStance operates across multiple states in the United States and combines company-operated clinics with telehealth services.